- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02929758
Speed of Processing Training in Patients With Parkinson's Disease and Healthy Older Adults
The Effect of Speed of Processing Training on Pedestrian Behavior in Patients With Parkinson's Disease and Healthy Older Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pedestrian injury poses significant risk to healthy older adults and patients with Parkinson's disease. Several age-related changes, including slowing of visual processing speed, increase risky pedestrian behavior. Persons with Parkinson's disease (PD) are at even higher risk of pedestrian injury due to motor and non-motor symptoms. Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms including slowness, tremor, stiffness, and balance problems. Visual processing speed abnormalities, anxiety, and cognitive problems are common non-motor symptoms.
The Useful Field of View (UFOV®) test is a measure of visual processing speed. The UFOV® test is performed on a touch-screen computer that displays objects in the central and peripheral visual fields for brief durations. Successful performance on the test requires integration of visual sensory information and higher-order cognitive processing. Our own research has shown that the UFOV® test performance correlates with pedestrian behavior in PD patients.
Speed of Processing Training (SOPT) is a computer-based training that uses visual exercises to improve cognitive processing. The training involves identifying and localizing visual information quickly in increasingly demanding visual displays. SOPT has been demonstrated to improve performance on the UFOV test in healthy older adults and PD patients. It is hypothesized that SOPT training will improve pedestrian safety in healthy older adults and PD patients.
In the proposed study, we will use a within-subject, randomized, controlled, cross-over design to evaluate if a computer training program (Speed of Processing Training - SOPT) improves safe pedestrian behavior in patients with Parkinson's disease and in healthy older adults in a virtual reality pedestrian environment and if the effects of training persist long-term.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria Parkinson's disease Subjects:
- Subjects with a clinical diagnosis of idiopathic Parkinson's disease based on the presence of bradykinesia and one or both of the following: rest tremor and/or rigidity
- On stable medications for at least 4 weeks prior to entering the study and expected to not need any medication changes for the duration of the study
- Age ≥50 at the time of entry into the study
- Age of onset of Parkinson's disease 45 - 85 years old
- Asymmetric onset of PD
- Progressive motor symptoms of PD
- Hoehn and Yahr stages 1-4
- Ability to walk up and down a single stair step
- Access to a computer with internet
Exclusion Criteria Parkinson's disease Subjects:
- Atypical features indicative of a Parkinson's Plus disorder (Progressive Supranuclear Palsy, Multiple Systems Atrophy, Corticobasal Degeneration) including cerebellar signs, supranuclear gaze palsy, apraxia, prominent autonomic failure, or other cortical signs.
- Neuroleptic treatment at time of onset of Parkinsonism
- Active treatment with a neuroleptic at time of study entry
- History of multiple strokes with stepwise progression of Parkinsonism
- History of multiple head injuries
- Inability to walk without assistance, including a cane, wheelchair, or walker
- Cognitive dysfunction that would prevent subject's ability to perform virtual reality simulation, speed of processing training, or complete questionnaire
- Blindness
- Any medical condition that, based on discretion of the PI, would prevent the subject's ability to participate in the study
Inclusion Criteria Control Subjects:
- Age ≥50 at the time of entry into the study
- On stable medications for at least 4 weeks prior to entering the study and expected to not need any medication changes for the duration of the study
- Ability to walk up and down a single stair step
- Access to a computer with internet
Exclusion criteria Control Subjects:
- Parkinson's disease or other neurodegenerative disorder
- Inability to walk without assistance, including a cane, wheelchair, or walker
- Cognitive dysfunction that would prevent subject's ability to perform virtual reality simulation, speed of processing training, or complete questionnaires
- Blindness
- Any medical condition that, based on the discretion of the PI, would prevent the subject's ability to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Initial Training Group
Healthy Controls will receive initial SOPT training and will be compared against controls in the delayed training group and the PD subjects in the initial training group
|
This is a game-like program designed based on the UFOV.
It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour).
The duration of training will be 3 months.
Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
Other Names:
|
Active Comparator: Control Delayed Training Group
Healthy Controls will receive delayed SOPT training and will be compared against controls in the initial training group and the PD subjects in the delayed training group
|
This is a game-like program designed based on the UFOV.
It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour).
The duration of training will be 3 months.
Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
Other Names:
|
Other: PD Initial Training Group
PD subjects will received initial SOPT training and will be compared against PD subjects in the delayed training group and the control subjects in the initial training group
|
This is a game-like program designed based on the UFOV.
It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour).
The duration of training will be 3 months.
Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
Other Names:
|
Other: PD Delayed Training Group
PD subjects will receive delayed SOPT training and will be compared against PD subjects in the initial training group and the control subjects in the delayed training group
|
This is a game-like program designed based on the UFOV.
It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour).
The duration of training will be 3 months.
Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to contact
Time Frame: 3 months
|
Difference in time to contact between baseline and immediate post-training assessments in PD and healthy controls
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Useful Field of View (UFOV)
Time Frame: 3 months
|
Difference in UFOV total score between baseline and immediate post-training assessments in PD and healthy controls
|
3 months
|
Executive function (MoCA, Trails, Stroop)
Time Frame: 3 months
|
Difference in MoCA, Trails, and Stroop between baseline and immediate post-training assessments in PD and healthy controls
|
3 months
|
Vigilance
Time Frame: 3 months
|
Differences in vigilance as measured by psychomotor vigilance task between baseline and immediate post-training assessments in PD and healthy controls
|
3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Amy Amara, MD, PhD, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- X150203003
- 5P30AG022838 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Clinical Trials on Speed of processing training (SOPT)
-
Kessler FoundationNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
University of Alabama at BirminghamCompleted
-
Kessler FoundationCompletedTraumatic Brain Injury | Mild Cognitive ImpairmentUnited States
-
Indiana UniversityCompleted
-
Kessler FoundationNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
University of Alabama at BirminghamNational Institute on Aging (NIA)TerminatedDelirium | DementiaUnited States
-
Hartford HospitalNational Institute of Mental Health (NIMH)Completed
-
University of RochesterNational Institute of Nursing Research (NINR)CompletedMild Cognitive ImpairmentUnited States
-
University of Alabama at BirminghamCompleted
-
University of Alabama at BirminghamNational Institute on Aging (NIA); Posit ScienceRecruitingStroke | Cognitive DysfunctionUnited States